Published in Br J Pharmacol on November 01, 1987
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85
A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol (1989) 6.30
Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest (1996) 4.98
Nitric oxide synthases: regulation and function. Eur Heart J (2011) 4.71
Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A (1990) 4.49
An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A (1990) 3.98
Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci U S A (1992) 3.72
Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A (1988) 2.84
The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol (2006) 2.70
Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest (1990) 2.61
Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol (2003) 2.26
cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A (1996) 2.17
Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad Sci U S A (1989) 2.08
Role of nitric oxide in maintaining vascular integrity in endotoxin-induced acute intestinal damage in the rat. Br J Pharmacol (1990) 1.94
Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest (1991) 1.91
Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest (1995) 1.55
Immediate release of a nitric oxide-like factor from bovine aortic endothelial cells by Escherichia coli lipopolysaccharide. Proc Natl Acad Sci U S A (1990) 1.54
Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci U S A (1988) 1.51
Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol (2011) 1.51
Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. J Clin Invest (1996) 1.50
Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci U S A (1991) 1.50
YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol (1995) 1.39
Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci U S A (1992) 1.39
Mechanisms of vein graft adaptation to the arterial circulation: insights into the neointimal algorithm and management strategies. Circ J (2010) 1.39
Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair (2008) 1.30
Acupuncture reduces experimental renovascular hypertension through mechanisms involving nitric oxide synthases. Microcirculation (2006) 1.26
Nitric oxide synthase in cultured endocardial cells of the pig. Br J Pharmacol (1991) 1.26
Peroxynitrite inhibits leukocyte-endothelial cell interactions and protects against ischemia-reperfusion injury in rats. J Clin Invest (1997) 1.24
A new class of organic nitrates: investigations on bioactivation, tolerance and cross-tolerance phenomena. Br J Pharmacol (2009) 1.24
Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev (2010) 1.18
Neointimal hyperplasia associated with synthetic hemodialysis grafts. Kidney Int (2008) 1.18
Role of reactive oxygen and nitrogen species in the vascular responses to inflammation. Free Radic Biol Med (2011) 1.17
Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol (2011) 1.17
Metabolism of glyceryl trinitrate to nitric oxide by endothelial cells and smooth muscle cells and its induction by Escherichia coli lipopolysaccharide. Proc Natl Acad Sci U S A (1992) 1.16
Time-dependent enhancement or inhibition of endotoxin-induced vascular injury in rat intestine by nitric oxide synthase inhibitors. Br J Pharmacol (1994) 1.15
Inorganic/Organic Hybrid Silica Nanoparticles as a Nitric Oxide Delivery Scaffold. Chem Mater (2008) 1.15
Nitric oxide from vascular smooth muscle cells: regulation of platelet reactivity and smooth muscle cell guanylate cyclase. Br J Pharmacol (1991) 1.14
Fluorinated xerogel-derived microelectrodes for amperometric nitric oxide sensing. Anal Chem (2008) 1.14
A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol (2001) 1.13
Laser-induced endothelial cell activation supports fibrin formation. Blood (2010) 1.12
The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors. Br J Pharmacol (1990) 1.11
Adventures in vascular biology: a tale of two mediators. Philos Trans R Soc Lond B Biol Sci (2006) 1.10
Vasoconstrictor prostanoids. Pflugers Arch (2010) 1.09
Historical perspective and future directions in platelet research. J Thromb Haemost (2011) 1.06
Prostacyclin releases endothelium-derived relaxing factor and potentiates its action in coronary arteries of the pig. Br J Pharmacol (1988) 1.06
The nitric oxide-endothelin-1 connection. Heart Fail Rev (2003) 1.06
Effects of slow, sustained, and rate-tunable nitric oxide donors on human aortic smooth muscle cells proliferation. Chem Biol Drug Des (2011) 1.06
Nitric oxide induces Zn2+ release from metallothionein by destroying zinc-sulphur clusters without concomitant formation of S-nitrosothiol. Biochem J (1999) 1.04
C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci U S A (2005) 1.04
Neuronal nitric oxide synthase (NOS) regulates leukocyte-endothelial cell interactions in endothelial NOS deficient mice. Br J Pharmacol (2001) 1.04
Amorphous silica nanoparticles trigger nitric oxide/peroxynitrite imbalance in human endothelial cells: inflammatory and cytotoxic effects. Int J Nanomedicine (2011) 1.04
Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest (1997) 1.04
Nitric oxide inhibits capacitative Ca2+ entry and enhances endoplasmic reticulum Ca2+ uptake in bovine vascular endothelial cells. J Physiol (2002) 1.04
Exercise training enhanced myocardial endothelial nitric oxide synthase (eNOS) function in diabetic Goto-Kakizaki (GK) rats. Cardiovasc Diabetol (2008) 1.03
Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem J (1997) 1.02
Deficiency of prostacyclin production in meningococcal shock. Arch Dis Child (1991) 1.01
Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Br J Pharmacol (1995) 1.00
Reversible NO motion in crystalline [Fe(Porph)(1-MeIm)(NO)] derivatives. Inorg Chem (2008) 1.00
Endothelial effects of antihypertensive treatment: focus on irbesartan. Vasc Health Risk Manag (2008) 0.99
Nitric oxide. Ann Rheum Dis (1996) 0.99
Mapping NO movements in crystalline [Fe(Porph)(NO)(1-MeIm)]. J Am Chem Soc (2009) 0.98
cGMP inhibits IP3-induced Ca2+ release in intact rat megakaryocytes via cGMP- and cAMP-dependent protein kinases. J Physiol (1998) 0.98
Influence of S-nitrosothiols and nitrate tolerance in the rat gastric fundus. Br J Pharmacol (1994) 0.97
Dysregulation of L-arginine metabolism and bioavailability associated to free plasma heme. Am J Physiol Cell Physiol (2010) 0.97
S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br J Pharmacol (2000) 0.97
Role of eNOS phosphorylation at Ser-116 in regulation of eNOS activity in endothelial cells. Vascul Pharmacol (2007) 0.96
Nitroprusside differentially inhibits ADP-stimulated calcium influx and mobilization in human platelets. Biochem J (1989) 0.96
Platelet inhibition by endothelium-derived relaxing factor from the rabbit perfused aorta. Br J Pharmacol (1988) 0.96
Human vascular smooth muscle cells inhibit platelet aggregation when incubated with glyceryl trinitrate: evidence for generation of nitric oxide. Br J Pharmacol (1991) 0.96
Effects of relaxin on mast cells. In vitro and in vivo studies in rats and guinea pigs. J Clin Invest (1994) 0.95
Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan. Br J Pharmacol (1992) 0.95
Tetragonal to triclinic--a phase change for [Fe(TPP)(NO)]. Inorg Chem (2009) 0.95
Amorphous silica nanoparticles aggregate human platelets: potential implications for vascular homeostasis. Int J Nanomedicine (2012) 0.95
Role of NAD(P)H oxidase in superoxide generation and endothelial dysfunction in Goto-Kakizaki (GK) rats as a model of nonobese NIDDM. PLoS One (2010) 0.94
Arginine and citrulline and the immune response in sepsis. Nutrients (2015) 0.93
Biocompatibility screening in cardiovascular implants. Z Kardiol (2005) 0.93
Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclin. Br J Pharmacol (2001) 0.91
Polyurethane with tethered copper(II)-cyclen complex: preparation, characterization and catalytic generation of nitric oxide from S-nitrosothiols. Biomaterials (2008) 0.91
Comparative pharmacology of analogues of S-nitroso-N-acetyl-DL-penicillamine on human platelets. Br J Pharmacol (1994) 0.91
Interactions of constitutive nitric oxide with PAF and thromboxane on rat intestinal vascular integrity in acute endotoxaemia. Br J Pharmacol (1994) 0.90
Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine. J Clin Invest (1995) 0.89
Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation. Br J Pharmacol (1989) 0.88
Nitric oxide, platelet function, myocardial infarction and reperfusion therapies. Heart Fail Rev (2003) 0.88
Endogenous and exogenous nitrates and their role in myocardial ischaemia. Br J Clin Pharmacol (1992) 0.88
Pharmacology of endothelium-derived nitric oxide and nitrovasodilators. West J Med (1991) 0.88
Cyclosporin treatment does not impair the release of nitric oxide in human coronary arteries. Br Heart J (1991) 0.87
A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations. Br J Pharmacol (2005) 0.87
The role of platelets in the recruitment of leukocytes during vascular disease. Platelets (2015) 0.87
Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy. Br J Pharmacol (2000) 0.86
Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol (1999) 0.86
Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide. Proc Natl Acad Sci U S A (2013) 0.86
The role of caveolae in endothelial cell dysfunction with a focus on nutrition and environmental toxicants. J Cell Mol Med (2010) 0.86
The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide. Br J Pharmacol (2010) 0.85
Skeletal muscle function during exercise-fine-tuning of diverse subsystems by nitric oxide. Int J Mol Sci (2013) 0.85
Role of vitamins C and e in regulating antioxidant and pro-oxidant markers in preeclampsia. J Clin Biochem Nutr (2008) 0.85
The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects. PPAR Res (2008) 0.85
On the epigenetics of vascular regulation and disease. Clin Epigenetics (2012) 0.85
Water-soluble poly(ethylenimine)-based nitric oxide donors: preparation, characterization, and potential application in hemodialysis. Biomacromolecules (2006) 0.85
Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis. J Am Soc Nephrol (2009) 0.84
Extending the use of autologous arterial conduits in myocardial revascularisation. Br Heart J (1992) 0.84
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
THE AGGREGATION OF BLOOD PLATELETS. J Physiol (1963) 10.00
Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (1986) 9.93
The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol (1984) 6.74
Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23
Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol (1986) 4.23
A radioimmunoassay for 6-keto-prostaglandin F1alpha. Prostaglandins (1978) 4.13
Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol (1986) 3.66
An improved method for washing of human platelets with prostacyclin. Thromb Res (1983) 3.07
Prostacyclin is not a circulating hormone in man. Prostaglandins (1982) 2.46
Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br J Pharmacol (1987) 2.30
Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin. Br J Pharmacol (1982) 2.01
Blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation of rabbit aorta by certain ferrous hemoproteins. J Pharmacol Exp Ther (1985) 2.00
Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (1986) 9.93
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85
Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A (1989) 8.34
Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci U S A (1989) 7.79
L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun (1988) 7.77
Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69
Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol (1989) 6.87
Nitric oxide synthases in mammals. Biochem J (1994) 6.50
A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol (1989) 6.30
Altered immune responses in mice lacking inducible nitric oxide synthase. Nature (1995) 6.20
Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. JAMA (2001) 6.02
Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol (1990) 5.87
Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 5.36
Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23
A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun (1989) 5.14
Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66
Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 4.55
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A (1990) 4.49
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol (1986) 4.23
Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 4.19
Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol (1988) 4.16
Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11
An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A (1990) 3.98
A randomized trial of care in a hospital medical unit especially designed to improve the functional outcomes of acutely ill older patients. N Engl J Med (1995) 3.77
Relation between symptoms of depression and health status outcomes in acutely ill hospitalized older persons. Ann Intern Med (1997) 3.76
Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74
Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet (1978) 3.74
Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J (1989) 3.70
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
Widespread tissue distribution, species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases. FEBS Lett (1991) 3.43
Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med (1979) 3.29
Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A (1995) 3.28
Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28
The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun (1987) 3.25
Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci U S A (1991) 3.22
Does delirium contribute to poor hospital outcomes? A three-site epidemiologic study. J Gen Intern Med (1998) 3.21
Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20
Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res (1992) 3.15
Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun (1990) 3.14
Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci U S A (1998) 3.10
An improved method for washing of human platelets with prostacyclin. Thromb Res (1983) 3.07
Control of regional blood flow by endothelium-derived nitric oxide. Hypertension (1990) 2.93
Functional status before hospitalization in acutely ill older adults: validity and clinical importance of retrospective reports. J Am Geriatr Soc (2000) 2.92
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun (1991) 2.79
Nitric oxide from L-arginine stimulates the soluble guanylate cyclase in adrenal glands. Biochem Biophys Res Commun (1989) 2.73
Nitric oxide synthase activities in human myocardium. Lancet (1993) 2.72
Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A (1994) 2.70
Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit. Br J Pharmacol (1989) 2.68
Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins (1977) 2.67
Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis (1992) 2.63
Chemokinetic activity of arachidonic and lipoxygenase products on leuocyctes of different species. Prostaglandins (1980) 2.59
Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis (1989) 2.58
NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol (1989) 2.53
Arrest of preterm labour and prolongation of gestation with glyceryl trinitrate, a nitric oxide donor. Lancet (1994) 2.53
Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull (1978) 2.51
Production of hydroxyl radicals from the simultaneous generation of superoxide and nitric oxide. Biochem J (1992) 2.51
Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48
Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet (1992) 2.44
Measuring prognosis and case mix in hospitalized elders. The importance of functional status. J Gen Intern Med (1997) 2.42
S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol (1992) 2.39
The role of TH1 and TH2 cells in a rodent malaria infection. Science (1993) 2.38
Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol (1992) 2.32
Acetylcholine induces vasodilatation in the rabbit isolated heart through the release of nitric oxide, the endogenous nitrovasodilator. Br J Pharmacol (1988) 2.32
Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun (1990) 2.31
Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem Biophys Res Commun (1990) 2.31
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins (1976) 2.28
Nitric oxide synthase activity in human gynecological cancer. Cancer Res (1994) 2.27
Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol (1999) 2.26